Limits...
Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis.

Luerce TD, Gomes-Santos AC, Rocha CS, Moreira TG, Cruz DN, Lemos L, Sousa AL, Pereira VB, de Azevedo M, Moraes K, Cara DC, LeBlanc JG, Azevedo V, Faria AM, Miyoshi A - Gut Pathog (2014)

Bottom Line: Only one strain, L. lactis NCDO 2118, was able to reduce IL-1β-induced IL-8 secretion in Caco-2 cells, suggesting a potential anti-inflammatory effect.This protective effect was not attributable to changes in secretory IgA (sIgA); however, NCDO 2118 administration was associated with an early increase in IL-6 production and sustained IL-10 production in colonic tissue.Here, we identified a new probiotic strain with a potential role in the treatment of IBD, and we elucidated some of the mechanisms underlying its anti-inflammatory effect.

View Article: PubMed Central - HTML - PubMed

Affiliation: Departamento de Biologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627 - 31270-901 Belo Horizonte, MG, Brazil.

ABSTRACT

Background: Many probiotic bacteria have been described as promising tools for the treatment and prevention of inflammatory bowel diseases (IBDs). Most of these bacteria are lactic acid bacteria, which are part of the healthy human microbiota. However, little is known about the effects of transient bacteria present in normal diets, including Lactococcus lactis.

Methods: In the present study, we analysed the immunomodulatory effects of three L. lactis strains in vitro using intestinal epithelial cells. L. lactis NCDO 2118 was administered for 4 days to C57BL/6 mice during the remission period of colitis induced by dextran sodium sulphate (DSS).

Results: Only one strain, L. lactis NCDO 2118, was able to reduce IL-1β-induced IL-8 secretion in Caco-2 cells, suggesting a potential anti-inflammatory effect. Oral treatment using L. lactis NCDO 2118 resulted in a milder form of recurrent colitis than that observed in control diseased mice. This protective effect was not attributable to changes in secretory IgA (sIgA); however, NCDO 2118 administration was associated with an early increase in IL-6 production and sustained IL-10 production in colonic tissue. Mice fed L. lactis NCDO 2118 had an increased number of regulatory CD4(+) T cells (Tregs) bearing surface TGF-β in its latent form (Latency-associated peptide-LAP) in the mesenteric lymph nodes and spleen.

Conclusions: Here, we identified a new probiotic strain with a potential role in the treatment of IBD, and we elucidated some of the mechanisms underlying its anti-inflammatory effect.

No MeSH data available.


Related in: MedlinePlus

Oral administration of L. lactis NCDO 2118 prevented histological damage induced by colitis. Photograph (X100) of H&E-stained paraffin sections of a representative colon from control (A), DSS (B) and DSS + NCDO2118 (C) groups at day 21. (D) Histological scores of colon sections of DSS-colitis mice with or without oral administration of L. lactis. Values represent the means ± MSE (n = 6). **, p < 0.01, ***, p < 0.001.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4126083&req=5

Figure 3: Oral administration of L. lactis NCDO 2118 prevented histological damage induced by colitis. Photograph (X100) of H&E-stained paraffin sections of a representative colon from control (A), DSS (B) and DSS + NCDO2118 (C) groups at day 21. (D) Histological scores of colon sections of DSS-colitis mice with or without oral administration of L. lactis. Values represent the means ± MSE (n = 6). **, p < 0.01, ***, p < 0.001.

Mentions: The ability of L. lactis NCDO 2118 to prevent DSS-induced colonic damage was evaluated at the histological level. Colon sections from mice of the control group had an intact epithelium, a well-defined crypt length, and no neutrophil infiltration in the mucosal and submucosal layers (Figure 3A). In contrast, colon tissues from DSS-treated mice showed severe inflammatory lesions throughout the mucosa and submucosa (Figure 3B). Oral administration of L. lactis NCDO 2118 ameliorated the histological damage after the second colitis cycle but did not immediately improve the inflammatory status of the gut mucosa on day 14 (Figure 3C, D).


Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis.

Luerce TD, Gomes-Santos AC, Rocha CS, Moreira TG, Cruz DN, Lemos L, Sousa AL, Pereira VB, de Azevedo M, Moraes K, Cara DC, LeBlanc JG, Azevedo V, Faria AM, Miyoshi A - Gut Pathog (2014)

Oral administration of L. lactis NCDO 2118 prevented histological damage induced by colitis. Photograph (X100) of H&E-stained paraffin sections of a representative colon from control (A), DSS (B) and DSS + NCDO2118 (C) groups at day 21. (D) Histological scores of colon sections of DSS-colitis mice with or without oral administration of L. lactis. Values represent the means ± MSE (n = 6). **, p < 0.01, ***, p < 0.001.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4126083&req=5

Figure 3: Oral administration of L. lactis NCDO 2118 prevented histological damage induced by colitis. Photograph (X100) of H&E-stained paraffin sections of a representative colon from control (A), DSS (B) and DSS + NCDO2118 (C) groups at day 21. (D) Histological scores of colon sections of DSS-colitis mice with or without oral administration of L. lactis. Values represent the means ± MSE (n = 6). **, p < 0.01, ***, p < 0.001.
Mentions: The ability of L. lactis NCDO 2118 to prevent DSS-induced colonic damage was evaluated at the histological level. Colon sections from mice of the control group had an intact epithelium, a well-defined crypt length, and no neutrophil infiltration in the mucosal and submucosal layers (Figure 3A). In contrast, colon tissues from DSS-treated mice showed severe inflammatory lesions throughout the mucosa and submucosa (Figure 3B). Oral administration of L. lactis NCDO 2118 ameliorated the histological damage after the second colitis cycle but did not immediately improve the inflammatory status of the gut mucosa on day 14 (Figure 3C, D).

Bottom Line: Only one strain, L. lactis NCDO 2118, was able to reduce IL-1β-induced IL-8 secretion in Caco-2 cells, suggesting a potential anti-inflammatory effect.This protective effect was not attributable to changes in secretory IgA (sIgA); however, NCDO 2118 administration was associated with an early increase in IL-6 production and sustained IL-10 production in colonic tissue.Here, we identified a new probiotic strain with a potential role in the treatment of IBD, and we elucidated some of the mechanisms underlying its anti-inflammatory effect.

View Article: PubMed Central - HTML - PubMed

Affiliation: Departamento de Biologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627 - 31270-901 Belo Horizonte, MG, Brazil.

ABSTRACT

Background: Many probiotic bacteria have been described as promising tools for the treatment and prevention of inflammatory bowel diseases (IBDs). Most of these bacteria are lactic acid bacteria, which are part of the healthy human microbiota. However, little is known about the effects of transient bacteria present in normal diets, including Lactococcus lactis.

Methods: In the present study, we analysed the immunomodulatory effects of three L. lactis strains in vitro using intestinal epithelial cells. L. lactis NCDO 2118 was administered for 4 days to C57BL/6 mice during the remission period of colitis induced by dextran sodium sulphate (DSS).

Results: Only one strain, L. lactis NCDO 2118, was able to reduce IL-1β-induced IL-8 secretion in Caco-2 cells, suggesting a potential anti-inflammatory effect. Oral treatment using L. lactis NCDO 2118 resulted in a milder form of recurrent colitis than that observed in control diseased mice. This protective effect was not attributable to changes in secretory IgA (sIgA); however, NCDO 2118 administration was associated with an early increase in IL-6 production and sustained IL-10 production in colonic tissue. Mice fed L. lactis NCDO 2118 had an increased number of regulatory CD4(+) T cells (Tregs) bearing surface TGF-β in its latent form (Latency-associated peptide-LAP) in the mesenteric lymph nodes and spleen.

Conclusions: Here, we identified a new probiotic strain with a potential role in the treatment of IBD, and we elucidated some of the mechanisms underlying its anti-inflammatory effect.

No MeSH data available.


Related in: MedlinePlus